Cue Biopharma (CUE) Q2 2024 earnings summary

Executive summary

• Strategic corporate restructuring and a 25% workforce reduction in July 2024 prioritized autoimmune programs (CUE-401, CUE-501) and improved operational efficiency.

• Oncology programs (CUE-101, CUE-102) continue to mature, with CUE-101 showing strong efficacy in head and neck cancer and CUE-102 demonstrating anti-tumor activity.

• CUE-401, in partnership with Ono, is advancing toward lead candidate selection in early 2025; CUE-501 is progressing with ongoing strategic partnering discussions.

• Focused business model and strategic partnerships implemented to manage capital access risk while retaining oncology programs as data matures.

Financial highlights

• Collaboration revenue rose to $2.7M for Q2 2024 (up $1.3M YoY), mainly from the Ono agreement; six-month revenue was $4.4M (up $2.8M YoY).

• Net loss for Q2 2024 was $10.2M, improved from $13.2M in Q2 2023; six-month net loss was $22.5M, down from $26.2M YoY.

• Cash and cash equivalents were $30.0M as of June 30, 2024, down from $48.5M at year-end 2023.

• Operating expenses, including R&D and G&A, decreased year-over-year.

Outlook and guidance

• Cash reserves expected to fund operations through Q2 2025; additional capital will be needed beyond that period.

• Strategic focus on autoimmune programs aims to optimize capital requirements and drive near-term value.

• Phase 2 trial for CUE-101 contingent on securing alternative capital sources.